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min/1.73m 2 ). The associations attenuated after adjustments 
for parathyroid hormone (PTH), which was associated with 
higher LVMI (g/m 2.7 ) in subjects with low kidney function (re-
gression coefficient highest quartile 6.3, 95% CI: 0.2, 12.5). 
 Conclusion: This study showed no strong associations of 
25(OH)D with myocardial structure and function. However, 
PTH – a possible modifiable mediator in the relation between 
25(OH)D and myocardial structure – was positively associated 
with LVMI in subjects with low kidney function.
 Copyright © 2012 S. Karger AG, Basel
 Introduction
 Worldwide, vitamin D deficiency is highly prevalent 
among older people, and is mainly caused by lifestyle and 
environmental factors that limit sunlight exposure to the 
skin  [1] . Accumulating evidence suggests a role of low se-
rum 25-hydroxyvitamin D [25(OH)D], which is the stor-
age form of vitamin D, in the pathogenesis of various dis-
eases such as autoimmune disorders, several types of can-
cers and cardiovascular diseases (CVD)  [2, 3] .
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 Abstract
 Background and Aims: To investigate associations between 
baseline serum 25-hydroxyvitamin D [25(OH)D] levels and 
myocardial structure and function after 8 years of follow-up in 
older Dutch subjects.  Methods: We included 256 subjects of 
the Hoorn Study, a population-based cohort. They underwent 
a standardized 2-dimensional echocardiogram at baseline be-
tween 2000 and 2001, and again between 2007 and 2009. We 
studied the association of 25(OH)D quartiles with echocardio-
graphic measures of the left ventricular mass index (LVMI), left 
ventricular systolic function and markers of diastolic function 
using linear regression analyses.  Results: At baseline, subjects 
had a mean age of 67.4  8 5.2 years and 41.4% had prior car-
diovascular disease (CVD). Low serum 25(OH)D levels were 
only associated with higher LVMI at 8-year follow-up in sub-
jects without prior CVD and in subjects with low kidney func-
tion (median estimated glomerular filtration rate  ^  77.5 ml/
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 A few prospective studies have found an inverse asso-
ciation of 25(OH)D levels with CVD risk in subjects with-
out prior CVD. In the Health Professionals Follow-Up 
Study, men deficient in 25(OH)D ( ! 15 ng/ml) had a 2-fold 
higher risk of developing myocardial infarction in 10 
years compared to men with higher 25(OH)D levels ( 6 30 
ng/ml)  [2] . In the Framingham Offspring Study, subjects 
with severe 25(OH)D deficiency ( ! 10 ng/ml) had a near-
ly 2-fold higher risk of a first cardiovascular event after 5 
years of follow-up than subjects with higher levels of 
25(OH)D ( 1 15 ng/ml)  [3] .
 Furthermore, findings in kidney patients support the 
observation that 25(OH)D deficiency induces hypertro-
phic growth of cardiomyocytes. Myocardial hypertrophy 
can lead to increased left ventricular (LV) mass. Kidney 
patients who were treated with calcitriol, which is the ac-
tive form of vitamin D, showed regression of myocardial 
hypertrophy  [4, 5] . Thus, vitamin D deficiency may in 
part explain the increased risk of CVD for kidney pa-
tients  [4, 5] .
 Taken together, evidence supports the finding that low 
25(OH)D levels induce myocardial hypertrophy  [4–7] . 
This may suggest that cardiomyocytes require calcitriol 
for maintenance of myocardial function and could po-
tentially explain the changes in cardiac morphology re-
lated to low 25(OH)D levels. LV hypertrophy may precede 
to LV diastolic dysfunction  [8] and thereby 25(OH)D 
might also be associated with diastolic function.
 Recent epidemiological studies have highlighted para-
thyroid hormone (PTH) not only as a biomarker of vita-
min D status but also as an independent cardiovascular 
risk factor  [9, 10] . We therefore aimed to analyze PTH as 
an exposure variable. 
 The investigation of the association between 25(OH)D 
and PTH in relation to myocardial structure and func-
tion represents a relevant step in unraveling the role of 
mineral metabolism markers in the prevention of CVD. 
The aim of this prospective study was to investigate the 
associations of 25(OH)D and PTH with changes in echo-
cardiographic measures of myocardial structure and 
function in older men and women in the Netherlands.
 Methods
 Study Sample
 The Hoorn Study started in 1989, including 2,483 men and 
women aged 50–75 years from the Netherlands. Detailed descrip-
tions of the study concept have been published previously  [11] . 
The current study was done involving 655 subjects who had ex-
aminations between 2000 and 2001 (considered baseline)  [12] . Be-
tween 2007 and 2009, 214 subjects were not willing to participate 
in the follow-up examinations which resulted in 441 (67%) sub-
jects who remained for longitudinal examinations. 
 Subjects who already had LV systolic dysfunction (LV ejection 
fraction  ! 50%) or LV diastolic dysfunction (left atrial volume in-
dex  1 40 ml/m 2 ) at baseline (n = 34) were excluded. Subjects with-
out baseline vitamin D measurements (n = 65) or with no or un-
satisfactory data on echocardiography at follow-up (n = 13) were 
also excluded. Subjects without complete baseline and follow-up 
(n = 73) echocardiographic data were excluded since it would not 
be possible to study the change in echocardiographic data. Our 
study sample, therefore, consisted of 256 subjects for longitudinal 
analyses. All subjects provided written informed consent, and the 
Ethics Committee of the VU University Medical Center Amster-
dam approved the study.
 Vitamin D Status
 Vitamin D status was assessed by measuring serum 25(OH)
D levels with a competitive binding protein assay (DiasSorin, 
Stillwater, Minn., USA)  [13] , a valid marker of vitamin D status 
 [14] . The interassay coefficient of variation was 10–15%. Serum 
PTH was determined with an immunoradiometric assay (Inc-
star Corp., Stillwater, Minn., USA). Laboratory measurements 
were conducted at the VU University Medical Center, Amster-
dam.
 Echocardiographic Measures
 An ultrasound scanner (HP SONOS 5500; 2–4 MHz trans-
ducer, Andover, Mass., USA) was used to obtain an echocardio-
gram according to a standardized protocol. Two-dimensional and 
M-mode recordings were performed in parasternal long- and 
short-axis views, and apical four- and two-chamber views  [15] . A 
senior cardiologist inspected each echocardiogram to ensure the 
quality of the measurements. All recordings were digitally stored 
and analyzed off-line. 
 Several echocardiographic estimates were measured as previ-
ously described  [15] . In short, five estimates of myocardial struc-
ture and function were used: left ventricular mass index (LVMI, 
g/m 2.7 ); a second estimate of LV mass (LVMI/LV) volume index 
(ml  g/m 2 ); LV ejection fraction (%); left atrium volume index 
(LAVI) (ml/m 2 ), and a second estimate of diastolic function 
(LAV  LVMI in ml  g/m 2.7 ).
 Additional Measurements at Baseline
 Fasting glucose, postload glucose after an oral glucose toler-
ance test, fasting high-density lipoprotein cholesterol, low-densi-
ty lipoprotein cholesterol and triglycerides were measured as de-
scribed elsewhere  [12] . Waist circumference (cm) was measured 
at the level midway between the lowest rib and the iliac crest. 
Blood pressure (mm Hg) was measured at the right-upper arm 
after 5 min of rest in a sitting position using a random-zero sphyg-
momanometer (Hawksley-Gelma Ltd, UK) and the average of two 
consecutive measurements was used. Arterial hypertension was 
defined as systolic blood pressure  6 140 mm Hg, diastolic blood 
pressure  6 90 mm Hg and/or use of antihypertensive medication. 
As an estimate of kidney function, estimated glomerular filtra-
tion rate (eGFR) was calculated according to the modification of 
diet in the renal diseases formula  [16] . Subjects filled out question-
naires to obtain information on medication use, smoking status 
and education level  [13] .
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 Statistical Analysis
 Baseline characteristics, baseline echocardiographic data and 
changes in echocardiographic data over time are presented ac-
cording to sex- and season-specific 25(OH)D quartiles. These 
were used because of the described sex difference in 25(OH)D 
levels in our study  [13] and because of the well-known seasonal 
variations of 25(OH)D levels which are mainly attributed to an-
nual differences in sun exposure of the skin  [17] . We assumed that 
subjects in a specific 25(OH)D quartile are likely to remain in that 
quartile throughout the year, despite significant variations in ab-
solute 25(OH)D levels  [17] . Season classification was based on the 
date of blood sampling: winter (December–February), spring 
(March–May), summer (June–August), and autumn (September–
November). We used linear regression analyses to examine linear 
trends across 25(OH)D quartiles, using the categorical variable of 
25(OH)D as a continuous variable (sex- and season-specific quar-
tiles entered as 1–4). A   2  test was performed to test for trends in 
the categorical variables across the quartiles of 25(OH)D. Differ-
ences between follow-up and baseline myocardial structure and 
function measures were calculated to investigate changes over 
time within quartiles of 25(OH)D.
 Multiple linear regression analyses were used to study asso-
ciations between baseline 25(OH)D (quartiles) and estimates of 
myocardial structure and function after 8 years of follow-up: 
LVMI, LVMI/LV volume index, LV ejection fraction, LAVI, and 
LAV  LVMI. The highest 25(OH)D quartile was considered as the 
reference group. We adjusted for the baseline value by adding in-
dependent variables to the regression models (i.e. LVMI at follow-
up adjusted for baseline LVMI). The potential confounders con-
sidered were: waist circumference, BMI, physical activity, outdoor 
activities, blood pressure, cholesterol, triglycerides, glucose levels, 
antihypertensive drugs, lipid-lowering medication, beta-block-
ers, eGFR and PTH.
 The first model was only adjusted for age (years). The second 
model was additionally adjusted for baseline echocardiographic 
measurements and lifestyle and metabolic variables based on the 
literature  [18] or when regression coefficients changed by more 
than 10%: smoking status (yes/no), educational level (low, middle 
or high), outdoor activities (h/day), waist circumference (cm), 
low-density lipoprotein cholesterol (mmol/l) and use of lipid-low-
ering drugs (yes/no). Finally, we adjusted for PTH (pmol/l) which 
could confound but could also mediate the relationship between 
25(OH)D and myocardial structure and function (if the latter was 
the case, adjustment would be inappropriate). Additionally, we 
treated 25(OH)D as a continuous variable to increase statistical 
power, adjusted for season, sex, baseline LVMI, and lifestyle and 
metabolic variables as mentioned above.
 We tested for effect modification by prior CVD, because CVD 
treatment and self-care strategies could have already changed 
myocardial function. We also tested for effect modification by 
glucose tolerance status, according to which the subjects had been 
recruited. Furthermore, we tested for hypertension because this 
is a known risk factor for LV hypertrophy and we also tested for 
eGFR because low kidney function may result in lower conversion 
of 25(OH)D to active vitamin D  [16] . When significant interaction 
terms were found (p  ! 0.10), analyses were stratified accordingly. 
Statistical analyses were conducted using the statistical program 
PASW 17.0 (SPSS Inc., Chicago, Ill., USA). All reported p values 
were two-sided and values  ! 0.05 were considered statistically sig-
nificant.
 Results
 Baseline 25(OH)D levels and complete longitudinal 
echocardiographic data were available for 256 subjects. 
The mean 25(OH)D level was 57.6  8 19.1 nmol/l and 90 
subjects (35.2%) had 25(OH)D levels  ! 50 nmol/l. Baseline 
characteristics according to sex- and season-specific 
25(OH)D quartiles showed that subjects with lower 
25(OH)D levels were significantly older, had a larger 
waist circumference, higher blood pressure (systolic and 
diastolic), higher PTH levels and higher eGFR ( table 1 ). 
None of the baseline myocardial structure or function 
measures showed a significant trend across the 25(OH)D 
quartiles. Subjects in the second 25(OH)D quartile had 
the most favorable myocardial structure and function 
measures: LVMI, LVMI/LV volume index, LAVI and 
LAV  LVMI were the lowest, and ejection fraction was the 
highest. Changes in myocardial structure and function 
during 8 years of follow-up did not differ significantly 
between the 25(OH)D quartiles ( table 2 ). Included sub-
jects with a baseline and follow-up measurement were 
younger (67.4 vs. 69.7 years), had less hypertension (62 vs. 
67%) and lower waist circumference (93.1 vs. 94.1 cm) 
than subjects who had no follow-up measurements.
 Results of the linear regression analyses in which fol-
low-up echocardiographic measures were adjusted for 
their baseline values confirmed these findings by show-
ing no association between 25(OH)D quartiles and the 
estimates of myocardial structures and function. After 
adjustment for potential confounders (data not shown), 
there was also no difference between the 25(OH)D 
quartiles. We found no effect modification by prior 
CVD, glucose tolerance status, hypertension or eGFR in 
these associations, except for LVMI. We stratified the 
analyses for LVMI by prior CVD (yes/no) and median 
eGFR (low kidney function  ^  77.5 ml/min/1.73m 2  and 
high kidney function  1 77.5 ml/min/1.73m 2 ) because 
significant effect modification (p  ! 0.01) by these fac-
tors occurred for the association between 25(OH)D and 
LVMI.
 In subjects without prior CVD, the lowest 25(OH)D 
quartile had a significantly higher LVMI after 8 years 
than the highest quartile ( table 3 , model 1). These results 
were attenuated when adjusting for smoking status, edu-
cational level, outdoor activities, waist circumference, 
low-density lipoprotein cholesterol and lipid-lowering 
medication (model 2, p trend 0.133), and the lowest 
25(OH)D quartile lost its significance after adjusting for 
PTH (model 3, p trend 0.307). Similar results were seen 
when 25(OH)D was treated as a continuous variable: re-
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 Table 1. B aseline characteristics according to season- and sex-specific 25(OH)D quartiles
S erum 25(OH)D p trend 
quarti le 1a quartile 2a quartile 3a quartile 4a 
 Mean, nmol/l 
 Range (min–max), nmol/l 
34.8
15.0–60.8 
50.4
34.2–67.3 
63.1
49.6–79.8 
81.0
64.0–113.1 
 Demographics 
 n 60 66 67 63 
 Age, years 69.785.6b 66.885.0 66.984.9 66.384.4  <0.001 
 Females, % 51.7 51.5 50.7 50.8 0.999 
 Education level 
 Low, % 39.0 35.4 43.9 46.0 0.437 
 Intermediate, % 39.0 47.7 47.0 36.5 
 High, % 22.0 16.9 9.1 17.5 
 Prior CVD, % 46.7 37.9 37.3 44.4 0.631 
 Type 2 diabetes, % 23.3 12.5 17.9 14.3 0.391 
 Arterial hypertension, % 75.0 63.6 55.2 55.6 0.079 
 Lifestyle 
 Cigarette smokers, % 15.0 15.2 7.5 9.5 0.417 
 Physical activity, h/day 3.081.9 3.882.8 3.582.7 3.482.3 0.560 
 Outdoor activities, h/day 0.980.8 1.281.2 1.481.7 1.481.2 0.012 
 Adiposity 
 BMI 27.283.4 26.883.6 27.282.9 26.383.3 0.276 
 Waist circumference, cm 95.2810.4 93.4811.0 93.7811.0 90.0811.2 0.014 
 Metabolic variables 
 Systolic blood pressure, mm Hg  146.6820.6  140.4820.2  135.7818.0  135.9818.6 0.001 
 Diastolic blood pressure, mm Hg 86.3812.6 83.4811.6 80.3810.4 81.689.6 0.007 
 Fasting glucose, mmol/l 6.081.0 6.081.2 5.981.0 5.881.1 0.284 
 Postload glucose, mmol/l 6.982.4 6.882.0 7.182.6 6.582.0 0.465 
 HbA1c, % 5.980.7 5.980.6 5.880.5 5.880.5 0.060 
 Triglycerides, mmol/l 1.380.7 1.680.9 1.480.7 1.380.6 0.537 
 LDL cholesterol, mmol/l 3.580.9 3.880.9 3.881.0 3.680.7 0.715 
 HDL cholesterol, mmol/l 1.480.4 1.480.3 1.580.4 1.580.5 0.093 
 Parathyroid hormone, pmol/lc  6.982.4 6.584.2 5.781.7 5.181.4  <0.001 
 eGFR, ml/min/1.73m2 82.8816.2 80.2815.0 79.9818.1 76.0812.0 0.021 
 eGFR <60 ml/min/1.73m2, % 5.0 6.1 10.4 9.5 0.606 
 Echocardiographic measures 
 LVMI, g/m2.7 44.0814.3 37.9811.7 39.8810.0 39.8810.3 0.121 
 LVMI/LV volume index, ml  g/m2 1.880.5 1.680.4 1.880.6 1.780.4 0.730 
 Ejection fraction, % 62.786.8 64.388.0 62.086.7 63.687.4 0.949 
 LA volume index, ml/m2 23.488.0 22.387.2 22.585.6 23.186.4 0.905 
 LA volumea LVMI, ml  g/m2  2,03881,383  1,70581,435  1,7448736.7  1,7408857 0.205 
 HbA 1c = Hemoglobin A1c; HDL = high-density lipoprotein; LA = left atrium; LDL = low-density lipoprotein.
 a Vitamin D quartiles are season and sex specific and therefore values may overlap. 
 b Data are presented as percentages or mean 8 standard deviation. 
 c PTH n = 252.  
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gression coefficient for 25(OH)D and LVMI in subjects 
without prior CVD was –0.15 (95% CI: –0.25, –0.04) and 
was attenuated after adjusting for lifestyle and metabolic 
variables to –0.09 (95% CI: –0.20, 0.02). In subjects with 
prior CVD, there was no clear association.
 In subjects with low kidney function (eGFR  ^  77.5 
(ml/min/1.73m 2 ), only the lowest baseline 25(OH)D 
quartile had a significantly higher LVMI after 8 years 
than the highest quartile ( table  4 ). When adjusted for
potential confounders and PTH, the association dis-
appeared. In patients with high eGFR ( 1 77.5 ml/min/
1.73m 2 ), 25(OH)D levels were not associated with LVMI 
after 8 years.
 We performed additional analyses with PTH as the 
determinant, making sex- and season-specific quartiles 
of PTH with the lowest quartile as the reference group. 
We checked for effect modification which was only pres-
ent for PTH with kidney function and LVMI. Linear re-
gression analyses showed that PTH was positively associ-
ated with LVMI in subjects with low eGFR, with a sig-
nificant trend over the quartiles ( table 5 ). When PTH was 
used as a continuous variable, the results were similar in 
subjects with low kidney function (regression coefficient: 
1.1, 95% CI: 0.17, 2.1) and disappeared after adjusting for 
potential confounders. In subjects with high eGFR, PTH 
was not associated with LVMI.
 Table 2. E ight-year changes in myocardial structure and function measures according to season- and sex-specific 25(OH)D quartiles
Serum 25(OH)D 
1st quartile
(n = 60) 
2nd quartile
(n = 66) 
3rd quartile
  (n = 67) 
4th quartile
(n = 63) 
 p trend 
 Myocardial structure 
 LVMI, g/m2.7 1.5816.1 0.789.1 1.9810.7 0.0810.0  0.611 
 LVMI/LV volume index, ml  g/m2 0.280.7 0.380.7 0.280.7 0.280.7  0.656 
 Systolic function 
 Ejection fraction, %  –10.3811.4  –10.689.6 –7.089.8  –10.8811.5  0.783 
 Diastolic function 
 LA volume index, ml/m2 1.7811.0 2.989.5 3.287.3 1.489.9  0.878 
 LA volume  LVMI, ml  g/m2.7 88.581,158 2408878 3928927 91.081,317  0.857 
 Dat a are presented as mean changes 8 standard deviation. LA = Left atrium; LV = left ventricle; LVMI = left ventricle mass index. 
 
 
 Table 3. A ssociation of baseline 25(OH)D quartiles with LVMI (g/m2.7) after 8 years of follow-up, stratified by prior CVD at baseline
Serum 25(OH)D 
 LVMI 1st quartile 2nd quartile 3rd quartile  4th quartile  p trend 
 No prior CVD n = 32 n = 41 n = 42  n = 35 
 Model 1  8.6 (2.6, 14.7) 2.5 (–3.1, 8.1) 4.6 (–0.9, 10.0)  reference  0.019 
 Model 2 6.0 (0.4, 11.6) 0.8 (–4.2, 5.8) 3.9 (–0.9, 8.7)  reference  0.133 
 Model 3 4.8 (–0.9, 10.4)  –0.3 (–5.4, 4.7) 3.4 (–1.3, 8.2)  reference  0.307 
 Prior CVD n = 28 n = 25 n = 25  n = 28 
 Model 1   –1.0 (–6.8, 4.9)  –5.5 (–11.4, 0.5) 1.3 (–7.3, 4.6)  reference  0.433 
 Model 2  –3.7 (–9.2, 1.7)  –5.4 (–11.1, 0.4)  –2.7 (–8.3, 2.8)  reference  0.113 
 Model 3  –4.4 (–9.9, 1.1)  –6.0 (–11.7, 0.3)  –3.1 (–8.6, 2.5)  reference  0.068 
 A p ositive regression coefficient implies higher LVMI. Model 1: adjusted for age. Model 2: as model 1 and also adjusted for baseline 
LVMI, smoking status, educational level, outdoor activities, waist circumference, low-density lipoprotein cholesterol and use of lipid-
lowering medication. Model 3: as model 2 and also adjusted for PTH.  
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 Discussion
 In our study population of older subjects, only the low-
est 25(OH)D quartile was associated with LVMI in sub-
jects without prior CVD and in subjects with low kidney 
function. These associations were not independent of 
PTH since adjusting for PTH attenuated the associations.
 The association between 25(OH)D status and echocar-
diographic measures has not been studied extensively. 
The limited number of previous studies have been incon-
sistent in the relationship between 25(OH)D and echo-
cardiographic measures: two did  [19, 20] and three  [21–
23] did not find an association between 25(OH)D levels 
and echocardiographic measures. It should be noted that 
most subjects in these studies suffered from heart failure 
which makes it hard to compare their results to ours in a 
population-based study.
 In our study we observed effect modification by prior 
CVD and by kidney function (eGFR) with regard to the 
associations of 25(OH)D levels and LVMI. This suggests 
 Table 4. A ssociation of baseline 25(OH)D quartiles with LVMI (g/m2.7) after 8 years of follow-up, stratified by median glomerular fil-
tration rate at baseline
S erum 25(OH)D 
 LVMI 1s t quartile 2nd quartile 3rd quartile  4th quartile  p trend 
 eGFR ≤77.5 n = 23 n = 29 n = 37  n = 39 
 Model 1 9.9 (3.3, 16.6)  –2.3 (–8.4, 3.7) 2.3 (–3.3, 7.9)  reference  0.056 
 Model 2 6.2 (–0.2, 12.7)  –1.9 (–7.4, 3.6) 1.2 (–3.9, 6.3)  reference  0.265 
 Model 3 4.7 (–2.1, 11.5)  –2.7 (–8.3, 2.9) 0.5 (–4.6, 5.7)  reference  0.559 
 eGFR >77.5 n = 37 n = 37 n = 30  n = 24 
 Model 1  –0.5 (–6.3, 5.3)  –1.4 (–7.0, 4.2) 0.4 (–5.5, 6.3)  reference  0.706 
 Model 2  –1.7 (–7.1, 3.6)  –2.2 (–7.3, 3.0)  –0.3 (–5.6, 5.0)  reference  0.411 
 Model 3  –2.4 (–7.7, 2.9)  –3.1 (–8.2, 2.1)  –0.2 (–5.4, 5.0)  reference  0.243 
 A pos itive regression coefficient implies higher LVMI. Model 1: adjusted for age. Model 2: as model 1 and also adjusted for baseline 
LVMI, smoking status, educational level, outdoor activities, waist circumference, low-density lipoprotein cholesterol and use of lipid-
lowering medication. Model 3: as model 2 and also adjusted for PTH.  
 
 
 Table 5. A ssociation of baseline PTH quartiles with LVMI (g/m2.7) after 8 years of follow-up, stratified by median glomerular filtra-
tion rate at baseline
 S erum PTH 
 LVMI  1s t quartile 2nd quartile  3rd quartile  4th quartile p trend 
 eGFR ≤77.5  n = 29 n = 34  n = 31  n = 32 
 Model 1   reference 2.3 (–3.9, 8.4)  5.0 (–1.3, 11.2)  11.7 (5.4, 17.9)  <0.001 
 Model 2  reference  –0.3 (–6.0, 5.4)  3.7 (–2.0, 9.5) 6.8 (0.7, 12.8) 0.008 
 Model 3  reference  –0.3 (–6.1, 5.5)  3.8 (–2.0, 9.5) 6.3 (0.2, 12.5) 0.013 
 eGFR >77.5  n = 29  n = 32  n = 35  n = 30 
 Model 1   reference  1.7 (–3.7, 7.1)  4.7 (–0.6, 10.0)  2.8 (–3.7, 7.1) 0.183 
 Model 2  reference  1.6 (–3.3, 6.5)  2.8 (–1.9, 7.5)  2.7 (–2.3, 7.6) 0.237 
 Model 3  reference  1.7 (–3.3, 6.7)  3.0 (–1.9, 7.9)  2.8 (–2.3, 7.8) 0.235 
 A p ositive regression coefficient implies higher LVMI. Model 1: adjusted for age. Model 2: as model 1 and also adjusted for baseline 
LVMI, smoking status, educational level, outdoor activities, waist circumference, low-density lipoprotein cholesterol and use of lipid-
lowering medication. Model 3: as model 2 and also adjusted for 25(OH)D. 
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that it is more likely that 25(OH)D is involved in hyper-
trophic cell growth, which may result in higher LVMI in 
the long run, than in diastolic function  [24] . In subjects 
without prior CVD and in subjects with low kidney func-
tion, only the lowest 25(OH)D quartile was associated 
with higher LVMI. This could be due to the fact that ad-
verse effects of 25(OH)D may be confined to lower levels 
of 25(OH)D. 
 The findings in subjects with lower eGFR were not un-
expected given that kidney-specific 1  -hydroxylase ac-
tivity [which catalyzes 25(OH)D to calcitriol] parallels 
the decline in residual renal function  [25] . Decreased syn-
thesis of calcitriol already occurs at eGFR values  ! 90 ml/
min/1.73m 2   [16] . Stratification based on the median 
eGFR led to a stratum in which the subjects had an eGFR 
 ^  77.5 ml/min/1.73m 2  which suggests decreased syn -
 thesis of calcitriol. It was remarkable that the lowest 
25(OH)D quartile had a significantly higher eGFR than 
the other quartiles. An explanation could be that low 
25(OH)D may only be harmful in the case of low kidney 
function, although we cannot demonstrate this based on 
our observational data. 
 Small trials in renal patients did show significant as-
sociations between vitamin D and LVMI  [4, 5, 26] . Kid-
ney patients who were treated with calcitriol showed re-
gression of cardiac hypertrophy  [4, 5] . The kidney is the 
main source for circulating calcitriol which could imply 
that reduced amounts of circulating calcitriol limit the 
function of cardiomyocytes and induce myocardial pro-
liferation  [1, 16] . In subjects with prior CVD, opposite 
trends were observed as lower 25(OH)D levels were asso-
ciated with lower LVMI. CVD treatment and lifestyle 
changes in subjects with prior CVD may change myocar-
dial function, which could be an explanation for the low-
er LVMI in this subgroup.
 We noticed that the associations between 25(OH)D 
and LVMI in subjects without prior CVD and low kidney 
function were not independent of PTH. After adjusting 
for PTH the association of 25(OH)D and LVMI was at-
tenuated. As PTH could be a mediator of 25(OH)D and 
LVMI, we investigated PTH as a determinant in the rela-
tion with echocardiographic measures.
 PTH was significantly associated with higher LVMI
in subjects with a lower kidney function. This suggests 
that PTH is more strongly associated with LVMI than 
25(OH)D. Although PTH and 25(OH)D are strongly in-
terrelated, PTH levels can also be substantially influenced 
by other factors, e.g. calcium and phosphate intakes  [16] . 
The relationship between PTH and LVMI was only visi-
ble in subjects with lower eGFR. A rise in serum PTH is 
one of the first detectable mineral metabolism distur-
bances of chronic kidney disease  [27] . In our study, after 
adjustment for the residual eGFR (continuously), the ob-
served association for PTH in subjects with low eGFR 
was slightly more pronounced. A recent meta-analysis 
suggests that vitamin D supplementation decreases PTH 
in chronic kidney disease patients  [28] and low 25(OH)D 
predicts mortality in these patients  [29] . In addition, vi-
tamin D supplementation decreased mortality signifi-
cantly in elderly women  [30] . It should be elucidated 
whether improvements in mineral metabolism markers 
are important for cardiac outcomes  [31, 32] . 
 The observed positive association between serum 
PTH levels and LVMI is consistent with the results of oth-
er studies  [33, 34] . From clinical studies there are also in-
dications that PTH may contribute to the development of 
LV hypertrophy. In patients with end-stage renal disease 
who have secondary hyperparathyroidism  [35], and also 
in patients with primary hyperparathyroidism  [36], there 
is a strong relation between LVMI and PTH. The under-
lying mechanism is not completely known; however, 
PTH may influence intracellular signaling by an increase 
of intracellular calcium in the cardiomyocytes. PTH re-
ceptors have been demonstrated in the heart, and in vitro 
PTH induces hypertrophy of cardiomyocytes  [37] . In ad-
dition, PTH activates protein kinase C which could lead 
to hypertrophic growth and expression of fetal-type pro-
teins in cardiomyocytes  [37] . This hypertrophic effect of 
PTH might contribute to the increase in LVMI.
 A strength of this study is the detailed recordings of 
myocardial structure and function measurements over 
an extended period in a well-defined population-based 
cohort of older persons. Other studies have investigated 
25(OH)D and myocardial structure and function in a 
cross-sectional setting in heart failure patients  [19–21, 
23] , or in small clinical trials in kidney patients  [4, 5,
26] . Our study allowed us to prospectively investigate 
25(OH)D and myocardial structure and function in
older men and women which gives insight to the role of 
25(OH)D in cardiac diseases. There are also potential 
limitations of this work. The present study is a selected 
sample of the initial population-based cohort of the
Hoorn Study. Moreover, missing data on echocardio-
graphic measures may not have been missed at random, 
but be related to conditions such as obesity or underlying 
cardiac abnormalities. Therefore, generalizations about 
the associations of 25(OH)D and PTH with LVMI in the 
older population as a whole are limited, and are probably 
underestimated because subjects with more cardiac ab-
normalities were lost to follow-up. In addition, subgroup 
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analyses allowed us to get more insight into the underly-
ing mechanisms, although they may be underpowered. 
When treating 25(OH)D and PTH as continuous vari-
ables, the results were consistent; however, these analy - 
ses cannot take into account a threshold effect of low 
25(OH)D. Also, the observational design cannot exclude 
the possibility of reverse causation. Furthermore, this 
study was not designed to investigate longitudinal chang-
es in myocardial structure and function. It should also
be noted that we only had a single measurement of
25(OH)D and PTH which may not adequately reflect 
long-term status. Future studies could benefit from re-
peated follow-up measurements and a larger sample size. 
 In conclusion, 25(OH)D levels were not strongly asso-
ciated with myocardial structure and function. The as-
sociations were not independent of PTH since adjusting 
for PTH attenuated the associations. PTH was positively 
associated with LVMI in subjects with low kidney func-
tion and is a potentially modifiable mediator in the rela-
tion between 25(OH)D and myocardial structure in a 
general older population. Future studies that investigate 
determinants of CVD should consider PTH levels, espe-
cially in subjects with decreased kidney function. 
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